Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82902 | 1.00 | DRD2 (0.53) | DRD2DRD3 | |
| SCHEMBL12695816 | 1.00 | DRD2 (0.53) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL13505422 | 0.98 | DRD2 (0.51) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL83201 | 0.98 | DRD2 (0.51) | DRD2DRD3 | |
| SCHEMBL503006 | 0.83 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL134338 | 0.83 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL503067 | 0.83 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL18290968 | 0.82 | DRD2 (0.57) | DRD2DRD3 | |
| SCHEMBL4249668 | 0.82 | DRD2 (0.57) | DRD2DRD3 | |
| SCHEMBL4242930 | 0.82 | DRD2 (0.57) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591550-A | Preparation method of molatinib and key intermediate | 沈阳药科大学 | 2025-03-11 | — | — | CN | claimed |
| CN-114761406-B | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4069693-B1 | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-20 | — | — | EP | claimed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | claimed |
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | claimed |
| CN-114761406-A | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | claimed |
| EP-3187490-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-04-06 | — | — | EP | claimed |
| WO-2021110614-A1 | HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-10 | — | — | WO | claimed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | claimed |
| CN-105793430-B | Process for the preparation of chiral 2-arylmorpholines | 豪夫迈·罗氏有限公司 | 2020-03-03 | — | — | CN | claimed |
| EP-3080284-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | F. Hoffmann-La Roche AG (CH) | 2016-10-19 | — | — | EP | claimed |
| CN-106008533-A | Cdk inhibitors | G1治疗公司 | 2016-10-12 | — | — | CN | claimed |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | HOFFMANN-LA ROCHE INC. (US) | 2016-10-06 | — | — | US | claimed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | claimed |
| CN-105793430-A | Process for the preparation of chiral 2-aryl morpholines | 豪夫迈·罗氏有限公司 | 2016-07-20 | — | — | CN | claimed |
| CN-102648217-B | Low molecular weight polymers of multifunctional multiple graft monomers | CASTROL LTD. (GB) | 2015-11-25 | — | — | CN | claimed |
| WO-2015086495-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-18 | — | — | WO | claimed |
| EP-2516392-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-31 | — | — | EP | claimed |
| EP-0697036-A1 | SILVER-CORROSION PROTECTION AGENT (II) | Henkel Kommanditgesellschaft auf Aktien (DE) | 1996-02-21 | — | — | EP | claimed |
| WO-1994026860-A1 | SILVER-CORROSION PROTECTION AGENT (II) | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1994-11-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | TLR7, TLR9, TLR5 | DRD2 1892/4885DRD3 2400/4885 |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | TAAR1, TAAR5, TACR2 | DRD2 182/4885DRD3 323/4885 |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | DRD2 596/4885DRD3 1047/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | DRD2 596/4885DRD3 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.